Skip to Content

Vinblastine Dosage

Applies to the following strength(s): 10 mg ; 1 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Breast Cancer

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Kaposi's Sarcoma

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Testicular Cancer

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Hodgkin's Disease

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Mycosis Fungoides

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Choriocarcinoma

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Lymphoma

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Adult Dose for Histiocytosis

Initial Dose: 3.7 mg/m2 intravenously over approximately one minute, once.

Because of the variation in the depth of the leukopenic response following therapy, the manufacturer recommends that vinblastine not be given more frequently than once every 7 days. However, there are several multiple day regimens where the dose is split into several consecutive days.

The manufacturer outlines the following conservative incremental approach to dosage at weekly intervals for adults. Therapy may be continued at 5.5 mg/m2 for the second dose, 7.4 mg/m2 for the third dose, 9.25 mg/m2 for the fourth dose, and 11.1 mg/m2 for the fifth dose. This progression may be followed up to a maximum dosage of 18.5 mg/m2. Dosage regimens may vary in clinical practice according to the disease being treated and the combination of antineoplastic agents being used.

White blood cell counts should be obtained just prior to dosage administration. The nadir in the white blood cell count is generally observed from 5 to 10 days following the dosage. Recovery to pretreatment levels is usually observed from 7 to 14 days after treatment. If a dose reduces the white cell count to approximately 3,000 cells/mm3, the next dose should not be given until the white cell count has returned to at least 4,000/mm3. The previous dosage increment may then be administered at weekly intervals for maintenance. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase subsequent doses.

The manufacturer states that the use of small amounts of vinblastine daily for long periods of time is not advisable and that strict adherence to the recommended dosage schedule is very important.

The duration of maintenance therapy varies according to the disease being treated and the combination of antineoplastic agents being used. Prolonged chemotherapy for maintaining remissions involves several risks, including life-threatening infectious diseases, sterility and the appearance of other cancers through suppression of immune surveillance. These risks must be balanced with potential benefits of therapy.

Usual Pediatric Dose for Malignant Disease

Hodgkin's disease: 2.5 to 6 mg/m2/day once every one to two weeks for three to six weeks. The maximum weekly dose is 12.5 mg/m2.

Histiocytosis: 0.4 mg/kg once every seven to ten days.

Germ cell tumor: 0.2 mg/kg on days one and two of the cycle every three weeks for four cycles.

Liver Dose Adjustments

The manufacturer recommends a 50% dose reduction for patients having a direct serum bilirubin value above 3 mg/100 mL. However, some authors recommend a reduction of 50% for a serum bilirubin value from 1.5 to 3.0 mg/100 mL and 75% for a value above 3.0 mg/100 mL.

Precautions

Vinblastine is a vesicant. (Vesicants are usually given through the side port of a running IV.) Extreme care should be taken to ensure that the needle is properly positioned before the injection is administered.

Other Comments

The patient should be:
warned to immediately report the appearance of sore throat, fever, chills, and/or sore mouth
made aware that alopecia may occur, but that scalp hair may regrow to its pretreatment extent even with continued treatment
made aware that jaw pain and pain in the organs containing tumor tissue may occur
advised to avoid constipation and that nausea and vomiting (although not common) may occur
informed to report any other serious medical event to the physician.

Hide